25 completed. 25 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Dengue Fever: new trials by email Literature Review of Dengue Fever trials Research Report on Dengue Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults TDV - Dengue Fever | Phase 2 | Completed | Takeda | 30 | 2018-12-28 | 2025-09-08 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1050 | 2016-05-02 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) - Dengue Fever | Phase 2 | Completed | Takeda | 351 | 2015-06-03 | 2019-08-28 |
| Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV Placebo - Dengue Fever | Phase 2 | Completed | Takeda | 1800 | 2014-12-05 | 2020-02-24 |
| Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized - Dengue Fever | Phase 2 | Completed | Takeda | 1002 | 2014-08-06 | 2019-07-18 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine CYD Dengue Vaccine, Japanese Encephalitis Vaccine - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2013-11-05 | 2022-03-24 |
| Celgosivir as a Treatment Against Dengue celgosivir, placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Singapore General Hospital | 50 | 2012-07-01 | 2013-12-02 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus, Placebo: NaCl 0.9% solution - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 189 | 2012-03-01 | 2022-04-05 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 390 | 2011-12-06 | 2022-03-24 |
| A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus, OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines, Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi | 210 | 2010-01-01 | 2013-02-06 |
| Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America CYD Dengue Vaccine, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis - Dengue, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 600 | 2009-10-01 | 2022-03-24 |
| Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore CYD Dengue vaccine, NaCl + influenza virus or hepatitis A vaccine - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1198 | 2009-04-07 | 2022-03-21 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects CYD dengue vaccine serotypes (1, 2, 3, 4)., Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 180 | 2009-03-01 | 2022-04-05 |
| Efficacy and Safety of Dengue Vaccine in Healthy Children CYD Dengue Vaccine, Inactivated rabies virus vaccine, Placebo - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 4002 | 2009-02-01 | 2022-04-05 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-09-26 | 2022-04-05 |
Showing 20 of 25. Sign in to see all of them.
Dengue (25) · Severe Dengue (17) · Acquired Immunodeficiency Syndrome (1) · Virus Diseases (1) · Yellow Fever (1)
Arbovirus Infections (25) · Flaviviridae Infections (25) · Flavivirus Infections (25) · Hemorrhagic Fevers, Viral (25) · Infections (25) · Mosquito-Borne Diseases (25) · RNA Virus Infections (25) · Vector Borne Diseases (25) · Virus Diseases (24) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
Sodium Chloride (4) · ChimeriVax (2) · Dengue Vaccines (2) · Dosage Forms (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Hepatitis A Vaccines (1) · Japanese Encephalitis Vaccines (1) · Measles-Mumps-Rubella Vaccine (1) · Pneumococcal Vaccines (1) · Solutions (1) · Vaccines (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1) · adacel (1) · celgosivir (1)
Sanofi Pasteur, a Sanofi Company (13) · Takeda (5) · Sanofi (3) · U.S. Army Medical Research and Development Command (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Singapore General Hospital (1)
United States (5) · Singapore (4) · Colombia (3) · Mexico (3) · Philippines (3) · Puerto Rico (3) · Brazil (2) · Honduras (2) · Thailand (2) · Australia (1) · Bangladesh (1) · Dominican Republic (1) · India (1) · Japan (1) · Panama (1)
Alberto Santiago-Cornier, MD (1) · Anna Quintero, MD (1) · Clemente Diaz-Perez, MD (1) · Domingo Chardon-Feliciano, MD (1) · Evelyn Matta-Fontanet, MD (1) · Ines O. Esquilin-Rivera, MD (1) · Javier Morales-Ramirez, MD (1) · Jorge Bertran-Pasarell, MD (1) · Jose Rodriguez-Santana, MD (1) · Jose Tavarez-Valle, MD (1) · Luis Rodriguez-Carrasquillo, MD (1)
PMID 40099800, PMID 18337339, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24877997, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 27102820, PMID 27509020, PMID 28365225, PMID 29122463, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 31843269, PMID 32119591, PMID 32197107, PMID 32572472, PMID 32932330, PMID 33212067, PMID 33534885, PMID 33626291, PMID 33711074, PMID 33822015, PMID 35078666, PMID 35364022, PMID 41213642, PMID 41722532, PMID 42480195
2014 (4), 2018 (1)